NEW YORK, Jan. 30, 2020 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery systems, today announced the addition of Dr.
Julio Rosenstock to its Scientific
Advisory Board.
Dr. Rosenstock is the current Director of the Dallas Diabetes
Research Center at Medical City Dallas and a Clinical Professor of
Medicine at the University of Texas
Southwestern Medical Center, Dallas. He received his medical degree from
the University of Costa Rica School of Medicine and completed
Fellowships in Endocrinology and Diabetes at the Royal Postgraduate
Medical School, Hammersmith Hospital, London, UK, and at the University of Texas Southwestern Medical
Center. His clinical research efforts focus on exploring
novel agents and therapeutic strategies to improve glycemic
control. Over the last 30 years, he has participated in hundreds of
clinical trials and has had an active role in the development of
new oral agents and insulin preparations acting often as a lead
clinical investigator and scientific advisor. He has authored or
co-authored 296 peer-reviewed manuscripts and numerous abstracts.
Dr. Rosenstock is a member of the National Board of Directors of
the American Diabetes Association (ADA) and is currently an
Associate Editor of Diabetes Care.
"We are excited with the addition of Dr. Rosenstock to our
scientific advisory board, as he brings meaningful experience in
diabetes research, clinical trials and the development of new
pharmaceuticals to improve diabetes management. We believe Dr.
Rosenstock's contributions will be invaluable as we broaden the
scope and expertise of our Scientific Advisory Board and continue
the advancement of our oral insulin, ORMD-0801, program," said
Nadav Kidron, CEO of Oramed.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in
the field of oral delivery solutions for drugs currently delivered
via injection. Established in 2006, with offices in New
York and Israel, Oramed has developed a novel Protein
Oral Delivery (PODTM) technology that is based on more
than 30 years of research by scientists
at Jerusalem's Hadassah Medical Center. Oramed is seeking
to revolutionize the treatment of diabetes through its proprietary
lead candidate, ORMD-0801, which has the potential to be the
first commercial oral insulin capsule for the treatment of
Type 2 and Type 1 diabetes. The Company has completed multiple
Phase II clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration. In
addition, Oramed is developing an oral GLP-1 (Glucagon-like
peptide-1) analog capsule, ORMD-0901.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the advancement of our
ORMD-0801 program, the potential to be the first commercial oral
insulin capsule for the treatment of diabetes or revolutionizing
the treatment of diabetes with our products. In addition, historic
results of scientific research and clinical trials do not guarantee
that the conclusions of future research or trials will suggest
identical or even similar conclusions. These forward-looking
statements are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent
protection for our product candidates; competition from other
pharmaceutical or biotechnology companies; and our ability to
obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays
or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and
Exchange Commission.
Company Contact
Oramed Pharmaceuticals
Estee Yaari
Office: +972-2-566-0001
US: +1-844-9-ORAMED
Email: estee@oramed.com
View original
content:http://www.prnewswire.com/news-releases/oramed-appoints-dr-julio-rosenstock-to-its-scientific-advisory-board-300996001.html
SOURCE Oramed Pharmaceuticals Inc.